Biohit Oyj - Changes board/management/auditors

Changes in the Management Team of Biohit Oyj

BIOHIT OYJ STOCK EXCHANGE RELEASE ON 22 June 2011 AT 2:00 PM


Nina Hasu, MSc (Econ.), born 1970, has been appointed Financial Director and
member of the Management Team of Biohit Oyj as of 8th August, 2011, replacing
Tiina Hankonen. Hasu has previously worked as Business Controller at
UPM-Kymmene Wood Oy. 

***

Elina Ämmälä, M.Pol.Sc, born 1976, has been appointed Communications Director
of Biohit Oyj as of 8th August, 2011, replacing Josefin Hoviniemi. Prior to
entering the services of Biohit, Ämmälä worked as Director at Cocomms Oy, a
communications consulting company. 


Further information:

Jussi Heiniö
CEO, Biohit Oyj
Tel. +358 9 773 861, mobile +358 400 701180
jussi.heinio@biohit.com

Biohit in brief:

Biohit is a globally operating Finnish biotechnology company that was
established in 1988. The company's mission is to improve human health and
quality of life. The company follows a goal-directed and long-term innovation
and patenting strategy. 

Biohit works with scientific communities to produce new technologies, products
and services based on research results and innovations that can be used to
develop safe and cost-effective liquid handling solutions for laboratory work
as well as diagnostic tests for the early detection and prevention of diseases
of the gastrointestinal tract. The end users of Biohit's products are e.g. the
pharmaceutical industry, the food industry, research institutes and
universities as well as the public and private healthcare sectors. 

Biohit has two business segments: Liquid Handling and Diagnostics. Liquid
Handling products include electronic and mechanical pipettes, disposable tips
as well as pipette maintenance and calibration services. The Diagnostics
business comprises products and analysis systems for the early diagnosis and
prevention of gastrointestinal diseases, such as the blood-sample based
GastroPanel examination for the diagnosis of stomach illnesses and associated
risks, and Acetium capsules, which bind carcinogenic acetaldehyde in the
stomach. 

In 2010, Biohit's net sales were MEUR 40 and the company employed approximately
400 people. Biohit is headquartered in Helsinki, Finland, and has production
facilities in Helsinki, Kajaani and in Suzhou, China. It has subsidiaries in
France, Germany, the UK, Russia, India, China, Japan and the USA. The company
also has a representative office in Singapore. Biohit's products are also sold
through about 200 distributors in 70 countries. 

Biohit's Series B share is quoted on NASDAQ OMX Helsinki in the Small
Cap/Healthcare group and is traded under the code BIOBV. 

More information: www.biohit.com.